Mesoblast (NASDAQ:MESO) reported financial results for the first half of fiscal year 2026 on Friday, highlighting a decisive transition from a clinical-stage biotechnology firm to a commercial-scale operator.
The company posted total revenue of $51.3 million, a result underpinned by the rapid market penetration of its flagship cell therapy, Ryoncil (remestemcel-L), following its U.S. launch for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD).
The commercial rollout generated gross sales of $57 million, which translated to $48.7 million in revenue after gross-to-net adjustments.
This surge in top-line performance contributed to an improved net loss of $40.2 million, down from $47.9 million in the prior year period.
Mesoblast finished the half-year with $130 million in cash and bolstered its liquidity position by securing a $125 million five-year credit facility, providing a non-dilutive runway to support its expanding pipeline.
Operational milestones during the period have solidified the product’s commercial foundation.
Mesoblast has successfully onboarded 49 transplant centers, moving closer to its initial target of 64.
Furthermore, the Centers for Medicare & Medicaid Services (CMS) simplified provider access by issuing a product-specific HCPCS J-Code, which became effective on October 1, 2025.
This regulatory designation is expected to streamline reimbursement processes and encourage broader clinical adoption.
Beyond its current commercial success, Mesoblast is advancing its second-generation platform, rexlemestrocel-L, toward pivotal filings.
Clinical programs for chronic low back pain and heart failure are progressing toward Biologics License Applications (BLAs), representing significant "blockbuster" opportunities for the firm.
In its forward-looking guidance, management projected Ryoncil net revenue for fiscal year 2026 to range between $110 million and $120 million.